Study of blood cells in lung cancer treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how a drug called G-CSF affects certain immune cells and cancer stem cells in people with advanced lung cancer. The goal is to understand how these cells interact during chemotherapy and immunotherapy, which may help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lung cancer called adenocarcinoma that has spread or cannot be treated with local therapy.
- You are about to start or are receiving chemotherapy and immunotherapy as your first treatment.
- You do not have certain genetic changes (EGFR, ALK, or ROS1) in your cancer.
- You are not taking more than 10 mg of corticosteroids per day.
- You do not have an autoimmune disease or an active, uncontrolled HIV infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This study looks at a new blood test to predict how well standard-of-care chemotherapy plus immunotherapy works for people with advanced non-small cell lung cancer. It aims to personalize treatment by identifying patients who may benefit most, potentially improving outcomes and reducing unnecessary side effects.
This study collects tissue (and follows patients over time) to better understand the natural course of several types of chest cancers. It may help researchers learn which tests and treatments work best in different cancer types.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.